Trade Mark Journal No.2026/037 11 September 2026

UK00004435648 25 August 2026 (5)

ZIGLETZA

International priority date claimed: 1 June 2026 (United States of America) (99858000)

Class 5: Pharmaceutical preparations for immunotherapy treatment, cell therapy, and gene therapy; Pharmaceutical preparations for the treatment of auditory, hematological, gastrointestinal, neuromuscular, muscular, cardiovascular, metabolic, immunological, inflammatory, oncological, ophthalmological, neurological, musculoskeletal, bone, connective tissue, dermatological, infectious, autoimmune, nephrological, hepatological, allergic, genetic, respiratory, viral, and pulmonary diseases and disorders; pharmaceutical preparations for the treatment of pain; pharmaceutical preparations for the treatment of obesity.

Regeneron Pharmaceuticals, Inc.

Representative: Appleyard Lees IP LLP